Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation

Blood

Volumn 90, Issue 10, 1997, Pages 4206-4211

  Lokhorst, H M ^a   Schattenberg, A ^b   Cornelissen, J J ^b   Thomas, L L M ^b   Verdonck, L F ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IDARUBICIN; IFOSFAMIDE; MELPHALAN; PREDNISONE;

ADOPTIVE IMMUNOTHERAPY; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; RELAPSE; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 0030815867     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.10.4206     Document Type: Article

References (34)

1. Attal M, Harousseau J-C, Stoppa A-M, Sotto J-J, Fuzibet J-G, Rossi J-F, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R: A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335:91, 1996
2. Bensinger WI, Rowley SD, Demirer T, Lilleby K, Schifmann K, Clift RA, Appelbaum FR, Fefer A, Barnett T, Storb R, Chauncey T, Maziarz RT, Klarnet J, McSweeney P, Holmberg L, Maloney DG, Weaver CH, Buckner CD: High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J Clin Oncol 14:1447, 1996
3. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, Bracy D, Salmon S, Jacobson J, Crowley J, Tricot G: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89:789, 1997
4. Lokhorst HM, Sonneveld P, Wijermans PW, van Marwijk Kooy M, Meuwissen OJATh, van Oers MHJ, van de Griend R, Dekker AW: Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma. Br J Haematol 92:44, 1996
5. Bensinger WI, Buckner CD, Anasetti C, Clift R, Storb R, Barnett T, Chauncey T, Shulman H, Appelbaum FR: Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome. Blood 88:2787, 1996
6. Gahrton G, Tura S, Ljungman P, Bladé J, Brandt L, Cavo M, Facon T, Gratwohl A, Hagenbeek A, Jacobs P, De Lauernzi A, van Lint M, Michallet M, Nikoskelainen, Reiffers J, Samson D, Verdonck LF, de Witte T, Volin L: Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 13:1312, 1995
7. Björkstrand B, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J, Bladé J, Carlson K, Cavo M, Ferrant A, Goldstone AH, De Laurenzi A, Majolino I, Marcus R, Prentice HG, Remes K, Samson D, Sureda A, Verdonck LF, Volin L, Gahrton G: Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 88:4711, 1996
8. Tricot G, Vesole DH, Jagganath S, Hilton J, Munshi, Barlogie B: Graft-versus-myeloma effect: Proof of principle. Blood 87:1196, 1996
9. Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ: Graft-versus-myeloma effect in two cases. Lancet 347:800, 1996
10. Gore ME, Selby PJ, Viner C, Clark PI, Meldrum M, Millar B, Bell J, Maitland JA, Milan S, Judson IR, Zuiable A, Tillyer C, Slevin M, Malpas JS, McElwain TJ: Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 2:879, 1989
11. Thomas ED, Storb R, Clift RA, Fefer A, Johnson FA, Neiman PE, Lerner KG, Glucksberg H, Buckner CD: Bone marrow transplantation. N Engl J Med 292:895, 1975
12. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, Hackman R, Tsoi MS, Storb R, Thomas ED: Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study in 20 Seattle patients. Am J Med 69:204, 1980
13. Verdonck LF, van Blokland WTM, Bosboom-Kalsbeek EK, van Heugten HG, Tilanus MGJ, de Weger RA: Complete donor T cell chimerism is accomplished in patients transplanted with bone marrow grafts containing a fixed low number of T cells. Bone Marrow Transplant 18:389, 1996
14. Kögler G, Wolf HH, Heyll A, Arkesteijn G, Wernet P: Detection of mixed chimerism and leukemic relapse after allogeneic bone marrow transplantation in subpopulations of leucocytes by fluorescent in situ hybridization in combination with the simultaneous immunophenotypic analysis of interphase cells. Bone Marrow Transplant 15:41, 1995
15. Barlogie B, Smith L, Alexanian R: Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310:1353, 1984
16. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck LF, Niederwieser D, Rhee F, Mittermüller J, De Witte T, Holler E, Ansari H: Graft-versus-leukemia effect of donor lymphocyte transfusion in marrow grafted patients. Blood 86:2041, 1995
17. Porter DL, Roth MS, McGarigle C, Ferrara JLM, Antin JH: Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330:100, 1994
18. Mackinnon S, Papadopoulos B, Carabasi MH, Reich L, Collins NH, Boulad F, Castro-Malaspina H, Childs BH, Gillio AP, Kernan NA, Small TN, Young JW, O'Reilly RJ: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261, 1995
19. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 87:2195, 1996
20. Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, Tuinen P van, Horowitz MM, Flomenberg N: Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 82:2310, 1993
21. Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaille C, List A, Dalton W, Ognoskie N, Cherit A, Antin JH, Nemunaitis Y: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433, 1997
22. Gale RP, Champlin R: How does bone marrow transplant cure leukemia? Lancet 2:28, 1984
23. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, Buckner CD, Anasetti C, Appelbaum FR, Badger C, Beatty P, Bensinger W, Berenson R, Bigelow C, Cheever MA, Clift R, Deeg HJ, Doney K, Greenberg P, Hansen JA, Hill R, Loughran T, Martin P, Neiman P, Petersen FB, Singer J, Stewart P, Thomas ED: Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73:1720, 1989
24. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R: Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med 300:1068, 1979
25. Bär BM, Schattenberg EJ, Clemm C, Mensink EJ, Geurts van Kessel A, Smetsers TF, Knops GH, Linders EHP, de Witte T: Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol 11:513, 1993
26. Sullivan KM, Storb R, Buckner CD, Fefer A, Fisher L, Weiden PL, Witherspoon RP, Appelbaum FR, Banaji M, Hansen J, Martin P, Sanders JE, Singer J, Thomas ED: Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematological neoplasms. N Engl J Med 320:100, 1994
27. Soiffer RJ, Murray C, Gronin R, Ritz J: Effect of low-dose interleukin-2 on disease relapse after T-cell depleted allogeneic bone marrow transplantation. Blood 84:964, 1994
28. Sullivan KM, Storb R, Buckner CD, Fefer A, Fisher L, Weiden PL, Witherspoon RP, Appelbaum FR, Banaji M, Hansen J: Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 320:328, 1989
29. Tiberghien P, Raynolds CW, Keller J, Spence S, Deschaseaux M, Certoux J-M, Contassot E, Murphy WJ, Lyons R, Chiang Y, Hervé P, Longo DL, Ruscetti FW: Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood 84:1333, 1994
30. Keil F, Haas OA, Fritsch G, Kalhs P, Lechner K, Mannhalter C, Reiter E, Niederwieser D, Hoecker P, Greinix HT: Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: Lack of residual donor hematopoiesis predicts aplasia. Blood 89:3113, 1997
31. Bordignon C, Bonini C, Verzeletti S, Nobili N, Maggioni D, Traversari C, Giavazzi R, Servida P, Zappone E, Benazzi E: Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Hum Gene Ther 6:813, 1995
32. Munshi NC, Govindarajan R, Drake R, Ding LM, Iyer R, Saylors R, Kornbluth J, Marcus S, Chiang Y, Ennist D, Kwak L, Reynolds C, Tricot G, Barlogie B: Thymidine kinase (TK) genetransduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood 89:1334, 1997
33. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondon G, Seong D, Lee M, Gajewski J, Van Besien K, Khouri I: CD8-depleted lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86:4337, 1995
34. Slavin S, Ackerstein A, Weiss I, Nagler A, Or R, Naparstek E: Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. Cancer Invest 10:221, 1992